Etoposide
Etoposide is a chemotherapy medicine (a topoisomerase inhibitor) used with other cancer drugs to treat small cell lung cancer and refractory testicular cancer, depending on the product.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 9 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Etoposide is a chemotherapy medicine that breaks DNA in cancer cells by blocking the enzyme topoisomerase II; on the market since about 1983 and available generically, it is a standard partner to other drugs for small cell lung cancer and, as an injection, for testicular cancer that resisted earlier treatment. It is a demanding drug, and nausea, mouth sores and hair loss (which usually grows back) are what people notice most. Its boxed warning is severe bone marrow suppression, a drop in blood counts that can cause serious infection or bleeding; blood tests come before every cycle, and fever, chills or unusual bruising means calling your cancer team at once.
Clinical pearls
- Keep etoposide capsules in the refrigerator; the capsule dose runs higher than the IV dose, so the two are not interchangeable.
- During the infusion, speak up right away about wheezing, throat tightness, or pain and swelling where the IV goes in.
- If you take warfarin, etoposide can push your INR (clotting test) up, so expect more frequent checks during treatment.
- Etoposide can harm an unborn baby, so women and men with female partners need birth control for months afterward.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Avopef can cause severe bone marrow suppression, which can lead to serious infection or bleeding. This means your blood cell counts can drop dangerously low.
It should not be given if your neutrophil count is below 500 cells/mm³ or your platelets are below 50,000/mm³. Your blood counts will be checked before each dose and cycle, and at regular times during and after treatment. Report fever, chills, signs of infection, or unusual bleeding or bruising right away.
Patient information guide A plain-language walkthrough of Etoposide, written from its FDA label.
What Etoposide is used for
▾
Etoposide is a chemotherapy medicine used together with other cancer treatments.
- Small cell lung cancer: first-line treatment with other chemotherapy (Etopophos with cisplatin; Avopef with chemotherapy and immunotherapy; VePesid and Etoposide capsules and Etoposide Injection with other approved chemotherapy).
- Refractory testicular tumors/cancer: Etopophos, Avopef and Etoposide Injection products, in combination with other chemotherapy. Etoposide capsules and VePesid are not labeled for this use.
How Etoposide works
▾
Etoposide breaks DNA strands in cancer cells. It acts through the enzyme DNA topoisomerase II or through the formation of free radicals.
The damaged cells stop dividing, mainly at the G2 stage of the cell cycle, and then die.
Etoposide dosage
▾
Etoposide is given in repeated courses, usually over several days. Courses are repeated about every 3 to 4 weeks after recovery from side effects.
- Injections are given into a vein by a healthcare professional, slowly (for example, Avopef over 30 to 60 minutes).
- Capsules (Etoposide, VePesid) are taken by mouth and stored in the refrigerator.
- Doses are adjusted for other drugs that lower blood counts, prior radiation or chemotherapy, and kidney problems.
Follow your prescriber's directions and your label.
Dosing details from the FDA-approved label
From the Etoposide prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Refractory Testicular Cancer (Avopef, intravenous)
- 50 mg/m2 to 100 mg/m2 administered intravenously daily on Days 1 to 5, or 100 mg/m2 administered intravenously daily on Days 1, 3 and 5
- Repeat treatment cycles every 3 to 4 weeks
- Dilute to a final concentration of 0.2 to 0.4 mg/mL and infuse over 30 to 60 minutes
- Small Cell Lung Cancer (Avopef, intravenous)
- 35 mg/m2 administered intravenously daily on Days 1 to 4, or 50 mg/m2 administered intravenously daily on Days 1 to 5
- Repeat treatment cycles every 3 to 4 weeks
- Dilute to a final concentration of 0.2 to 0.4 mg/mL and infuse over 30 to 60 minutes
- Renal impairment, CLcr 15 to 50 mL/min, Refractory Testicular Cancer (Avopef)
- 37 mg/m2 to 75 mg/m2 Days 1 through 5, or 75 mg/m2 Days 1, 3 and 5
- Repeat cycles every 3 to 4 weeks
- No dosage modification for CLcr > 50 mL/min; dosage not established for CLcr < 15 mL/min
- Renal impairment, CLcr 15 to 50 mL/min, Small Cell Lung Cancer (Avopef)
- 26 mg/m2 Days 1 through 4, or 37 mg/m2 Days 1 through 5
- Repeat cycles every 3 to 4 weeks
- No dosage modification for CLcr > 50 mL/min; dosage not established for CLcr < 15 mL/min
- Refractory testicular tumors (Etopophos)
- 50 to 100 mg/m2 per day administered intravenously over 5 minutes to 3.5 hours on days 1 through 5, or 100 mg/m2 administered intravenously over 5 minutes to 3.5 hours on days 1, 3, and 5, of each 21-day (or 28-day cycle)
- In CLcr 15-50 mL/min, administer 75% of the recommended dose; do not give by bolus injection
- Small cell lung cancer (Etopophos)
- 35 mg/m2 per day administered intravenously over 5 minutes to 3.5 hours for 4 days, or 50 mg/m2 per day administered intravenously over 5 minutes to 3.5 hours for 5 days
- In CLcr 15-50 mL/min, administer 75% of the recommended dose
- Small cell lung cancer (VePesid oral capsules)
- Two times the IV dose rounded to the nearest 50 mg (i.e., two times 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days)
- Courses repeated at 3- to 4-week intervals
- Modify dosage for myelosuppressive effects of other drugs or prior x-ray therapy or chemotherapy; see PRECAUTIONS for renal impairment
- Testicular cancer (Etoposide Injection, USP)
- In combination with other approved chemotherapeutic agents, 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5
- Courses repeated at 3- to 4-week intervals
- See PRECAUTIONS for renal impairment dosing adjustments
- Small cell lung cancer (Etoposide Injection, USP)
- In combination with other approved chemotherapeutic drugs, 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days
- Courses repeated at 3- to 4-week intervals
- See PRECAUTIONS for renal impairment dosing adjustments
- Small cell lung cancer (Etoposide Capsules)
- Two times the IV dose rounded to the nearest 50 mg
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION: Note: Plastic devices made of acrylic or ABS (a polymer composed of acrylonitrile, butadiene, and styrene) have been reported to crack and leak when used with undiluted Etoposide Injection, USP. Etoposide Injection, USP The usual dose of Etoposide Injection, USP in testicular cancer in combination with other approved chemotherapeutic agents ranges from 50 to 100 mg/m 2 /day on days 1 through 5 to 100 mg/m 2 /day on days 1, 3, and 5. In small cell lung cancer, the Etoposide Injection, USP dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m 2 /day for 4 days to 50 mg/m 2 /day for 5 days. For recommended dosing adjustments in patients with renal impairment (see PRECAUTIONS ) . Chemotherapy courses are repeated at 3- to 4-week intervals after adequate recovery from any toxicity. Etoposide Capsules In small cell lung cancer, the recommended dose of etoposide capsules is two times the IV dose rounded to the nearest 50 mg. The dosage, by either route, should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior x-ray therapy or chemotherapy which may have compromised bone marrow reserve. Administration Precautions As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of etoposide. Skin reactions associated with accidental exposure to etoposide may occur. The use of gloves is recommended. If etoposide solution contacts the skin or mucosa, immediately and thoroughly wash the skin with soap and water and flush the mucosa with water. Preparation for Intravenous Administration Etoposide Injection, USP must be diluted prior to use with either 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, to give a final concentration of 0.2 to 0.4 mg/mL. If solutions are prepared at concentrations above 0.4 mg/mL, precipitation may occur. Hypotension following rapid intravenous administration has been reported, hence, it is recommended that the etoposide solution be administered over a 30- to 60-minute period. A longer duration of administration may be used if the volume of fluid to be infused is a concern. Etoposide should not be given by rapid intravenous injection.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Etoposide side effects
▾
Many people have side effects, and these are the most common:
Common side effects
- Low white blood cell counts, which raise infection risk
- Low platelet counts and anemia
- Nausea and vomiting
- Loss of appetite
- Diarrhea
- Mouth sores
- Hair loss, which is usually reversible
- Low white blood cells, platelets, or red blood cells
When to get medical help
- Fever, chills or other signs of infection, which can be serious when blood counts are low
- Unusual bleeding or bruising
- Signs of a severe allergic reaction during infusion: chills, fever, fast heartbeat, wheezing, trouble breathing, swelling of the face or tongue, throat tightness, or low blood pressure
- Pain, swelling or redness at the IV site, because leakage into the tissue can cause serious damage
- Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis
- Vision changes, seizures, or new lung symptoms such as cough or shortness of breath
Etoposide warnings and precautions
▾
- Severe bone marrow suppression can cause serious infection, bleeding, and death. Blood counts are monitored.
- Allergic and infusion reactions can be severe or fatal. Slow infusion helps prevent low blood pressure.
- Extravasation (IV leakage) can cause swelling, pain, cellulitis, and tissue death.
- Secondary leukemia has occurred.
- Low albumin can increase side effects.
- Harm to an unborn baby is possible.
Etoposide interactions
▾
Some medicines and substances can change how etoposide works or how safe it is.
- Strong CYP3A inhibitors may raise etoposide levels.
- Strong CYP3A inducers may lower etoposide levels and reduce effectiveness.
- Warfarin: INR can rise, so closer monitoring is needed.
- Aspirin, sodium salicylate, and phenylbutazone can displace etoposide from blood proteins in lab studies.
- Cisplatin is associated with slower clearance of etoposide.
- Avopef contains alcohol, which may affect driving right after infusion.
Interactions listed in the FDA-approved label
From the Etoposide prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP3A inhibitors: Etoposide is a CYP3A4 substrate; strong CYP3A inhibitors may increase etoposide exposure, which may increase the risk of AVOPEF-associated adverse reactions. Avoid concomitant use of strong CYP3A inhibitors.
- Strong CYP3A inducers: Etoposide is a CYP3A4 substrate; strong CYP3A inducers may reduce etoposide exposure, which may decrease the effectiveness of AVOPEF. Avoid concomitant use of strong CYP3A inducers.
- Vitamin K antagonists (warfarin): Co-administration of AVOPEF with warfarin can result in elevated international normalized ratio (INR). Monitor INR more frequently and modify the dosage of the vitamin K antagonists as appropriate.
Read the label’s full interactions text
7 DRUG INTERACTIONS CYP3A Inhibitors and CYP3A Inducers : Avoid concomitant use of strong CYP3A inhibitors and strong CYP3A inducers with AVOPEF. ( 7.1 ) Vitamin K Antagonists : Monitor INR more frequently and modify the dosage of the vitamin K antagonists as appropriate. Co-administration of AVOPEF with warfarin can result in elevated international normalized ratio (INR). ( 7.2 ) 7.1 Effect of Other Drugs on AVOPEF CYP3A Inhibitors Avoid concomitant use of strong CYP3A inhibitors. Etoposide is a CYP3A4 substrate. Strong CYP3A inhibitors may increase etoposide exposure, which may increase the risk of AVOPEF-associated adverse reactions [see Clinical Pharmacology (12.3) ]. CYP3A Inducers Avoid concomitant use of strong CYP3A inducers. Etoposide is a CYP3A4 substrate. Strong CYP3A inducers may reduce etoposide exposure, which may decrease the effectiveness of AVOPEF [see Clinical Pharmacology (12.3) ]. 7.2 Effect of AVOPEF on Other Drugs Vitamin K Antagonists Monitor INR more frequently and modify the dosage of the vitamin K antagonists as appropriate. Co-administration of AVOPEF with warfarin can result in elevated international normalized ratio (INR).
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Etoposide
▾
- Allergy to etoposide or its ingredients (a contraindication for Avopef).
- Pregnancy or possible pregnancy. Use effective contraception and tell your doctor right away.
- Breastfeeding: avoid during treatment and for 1 week after the last Avopef dose.
- Reduced kidney function: the dose is lowered for creatinine clearance of 15 to 50 mL/min.
- Low albumin levels.
- Age 65 or older: more side effects were reported.
- Children: Avopef safety and effectiveness are not established.
- Fertility effects are possible in women and men.
Etoposide overdose
▾
No proven antidote has been established for etoposide injection overdose. If you think too much was given or taken, contact your care team or poison control right away.
What Etoposide does in the body
▾
Etoposide causes DNA strand breaks, which stops cells at the G2 stage before they divide. At high concentrations it causes cells entering division to burst. At lower concentrations it stops cells from entering prophase. It does not interfere with microtubule assembly.
How your body processes Etoposide
▾
After IV dosing, etoposide leaves the blood in two phases, with a terminal half-life of about 4 to 11 hours. It is highly bound to blood proteins (97%) and enters the cerebrospinal fluid poorly. It is cleared by the kidneys and by metabolism and bile, partly through CYP3A4.
Capsules have an average bioavailability of about 50%, with a wide range of 25% to 75%.
How to store Etoposide
▾
Store at 20°C to 25° C (68°F to 77° F); excursions permitted to 15°C to 30°C (59°F to 86°F). store the partially used multiple-dose vial in the original carton at controlled room temperature, 20°C to 25°C (68°F to 77°F) for up to 28 days .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Etoposide
152 supplements and herbal products have documented interactions with Etoposide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 5
- Moderate · 107
- Minor · 40
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Etoposide: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Etoposide — the kind of thing our pharmacy team would talk through with you at the counter.
What is etoposide for?
▾
How will I get it?
▾
What side effects should I expect?
▾
When should I call my doctor?
▾
Can I take it with my other medicines?
▾
Is it safe in pregnancy?
▾
Is Etoposide available over the counter?
▾
When was Etoposide first available?
▾
Who makes Etoposide?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Etoposide on HelloPharmacist
Etoposide forms and strengths (how it comes)
Etoposide is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Etoposide inactive ingredients by manufacturer.
Injection
How this form is used
- Etopophos is used for refractory testicular tumors with other chemotherapy and for first-line small cell lung cancer with cisplatin.
- Avopef is used in adults for refractory testicular cancer and for first-line small cell lung cancer, with other chemotherapy and/or immunotherapy.
- Etoposide Injection is used with other chemotherapy for refractory testicular tumors and first-line small cell lung cancer.
- Avopef is diluted and given by IV infusion over 30 to 60 minutes to lower the risk of low blood pressure.
- Etopophos must not be given as a bolus (quick) injection.
- Etopophos dose is reduced to 75% for creatinine clearance of 15 to 50 mL/min.
- Etoposide Injection labels advise gloves for handling and warn that some acrylic or ABS plastic devices can crack and leak with undiluted product.
Capsule
How this form is used
- VePesid Capsules are used with other approved chemotherapy as first-line treatment of small cell lung cancer.
- Etoposide capsules are used with other approved chemotherapy as first-line treatment of small cell lung cancer.
- VePesid Capsules must be stored in the refrigerator.
- Etoposide capsules must be stored in the refrigerator.
- For VePesid and Etoposide capsules, wear impervious gloves when handling the blister packs.
- VePesid and Etoposide capsule doses are set at twice the IV dose in small cell lung cancer, so follow your prescriber's directions.
Etoposide on the U.S. market: products, makers and brands
How Etoposide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
10 companies list 19 Etoposide product records with the FDA, mostly as injection, capsule; the earliest marketing or approval year on record is 1983. Brand names on the directory include VePesid, Toposar, Etopophos and 1 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Etoposide is used (Medicaid data)
A general measure of how commonly Etoposide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Etoposide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Etoposide prescribed? Of the 1,601 medications we measure, Etoposide ranks #858 by Medicaid prescriptions — more than 46% of them.
Utilization by Etoposide product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
etoposide 20 MG/ML Injectable Solution Most dispensed
Summed across the 15 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310248
etoposide 100 MG Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1734340
etoposide 50 MG Oral Capsule
Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 197687
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Etoposide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 17 of 36 listed Etoposide NDCs with Medicaid activity.
Compare Etoposide products
A representative set of FDA-listed product records for Etoposide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 50 mg | Oral | Amneal Pharmaceuticals NY LLC | NDA | View NDC → |
| 50 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 50 mg | Oral | Onesource Specialty Pharma Limited | NDA | View NDC → |
| 💊Injection | ||||
| 20 mg/mL | Intravenous | Accord Healthcare Inc. | ANDA | View NDC → |
| 100 mg/5 mL | Intravenous | AVYXA Pharma, LLC | NDA | View NDC → |
| 500 mg/25 mL | Intravenous | AVYXA Pharma, LLC | NDA | View NDC → |
| 20 mg/mL | Intravenous | BluePoint Laboratories × 4 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 100 mg | Intravenous | H2-Pharma, LLC | NDA | View NDC → |
| 20 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. × 4 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Meitheal Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
Showing 19 of 19 products — FDA National Drug Code Directory. See every product, package size and price: browse all 19 Etoposide NDCs →
Etoposide side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Etoposide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Etoposide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Etoposide FDA approval history
How Etoposide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Etoposide recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Etoposide recalls since July 2021.
✅No Etoposide recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 4179 3 dose forms · 4 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 376890In current FDA listingsClinical drug / strength (SCD) 20 MG/MLRxCUI 310248 -
Dose form (SCDF) Injection RxCUI 1734339In current FDA listingsClinical drug / strength (SCD) 100 MGRxCUI 1734340 -
Dose form (SCDF) Oral Capsule RxCUI 372132In current FDA listings
Look up RxCUI 4179 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Etoposide supply and shortage status
Whether Etoposide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Etoposide brand names
Etoposide is sold under 4 brand names in the FDA directory — VePesid, Toposar, Etopophos, Avopef. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Etoposide: manufacturers and labelers
10 companies list Etoposide products with the FDA. By number of product records, the largest are BluePoint Laboratories, Hikma Pharmaceuticals USA Inc., Meitheal Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Etoposide drug class (RxNorm)
Etoposide belongs to the Topoisomerase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Etoposide page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Fresenius Kabi USA, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →